AU2021351500A1 - ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES - Google Patents

ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES Download PDF

Info

Publication number
AU2021351500A1
AU2021351500A1 AU2021351500A AU2021351500A AU2021351500A1 AU 2021351500 A1 AU2021351500 A1 AU 2021351500A1 AU 2021351500 A AU2021351500 A AU 2021351500A AU 2021351500 A AU2021351500 A AU 2021351500A AU 2021351500 A1 AU2021351500 A1 AU 2021351500A1
Authority
AU
Australia
Prior art keywords
amino acid
antibody
acid sequence
a2ar
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021351500A
Other languages
English (en)
Other versions
AU2021351500A2 (en
AU2021351500A9 (en
Inventor
Changyun HU
Shuying Liu
Xinyan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adept Biopharmaceutical And Technology Ltd
Na Biotech Corp
Original Assignee
Adept Biopharmaceutical And Tech Ltd
Na Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adept Biopharmaceutical And Tech Ltd, Na Biotech Corp filed Critical Adept Biopharmaceutical And Tech Ltd
Publication of AU2021351500A1 publication Critical patent/AU2021351500A1/en
Publication of AU2021351500A2 publication Critical patent/AU2021351500A2/en
Publication of AU2021351500A9 publication Critical patent/AU2021351500A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021351500A 2020-09-30 2021-09-30 ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES Pending AU2021351500A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085612P 2020-09-30 2020-09-30
US63/085,612 2020-09-30
PCT/US2021/052819 WO2022072601A1 (en) 2020-09-30 2021-09-30 ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES

Publications (3)

Publication Number Publication Date
AU2021351500A1 true AU2021351500A1 (en) 2023-06-08
AU2021351500A2 AU2021351500A2 (en) 2023-08-10
AU2021351500A9 AU2021351500A9 (en) 2024-09-05

Family

ID=80951827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021351500A Pending AU2021351500A1 (en) 2020-09-30 2021-09-30 ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES

Country Status (7)

Country Link
US (1) US20230340132A1 (https=)
EP (1) EP4222173A4 (https=)
JP (1) JP2023543896A (https=)
CN (1) CN116348140A (https=)
AU (1) AU2021351500A1 (https=)
CA (1) CA3194285A1 (https=)
WO (1) WO2022072601A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CN116333127B (zh) * 2022-06-28 2026-03-24 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN119303103A (zh) * 2023-07-11 2025-01-14 清华大学 一种抗体偶联物及其应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025257365A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Adenosine a2a antagonists for the treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP2011097869A (ja) * 2009-11-05 2011-05-19 Japan Science & Technology Agency 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体
WO2013040358A2 (en) * 2011-09-14 2013-03-21 University Of Washington Through Its Center For Commercialization Assays and compositions for detection of agr2
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20140322236A1 (en) * 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer

Also Published As

Publication number Publication date
AU2021351500A2 (en) 2023-08-10
JP2023543896A (ja) 2023-10-18
WO2022072601A1 (en) 2022-04-07
CN116348140A (zh) 2023-06-27
AU2021351500A9 (en) 2024-09-05
EP4222173A1 (en) 2023-08-09
CA3194285A1 (en) 2022-04-07
EP4222173A4 (en) 2024-10-30
US20230340132A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US12350333B2 (en) Checkpoint regulator antagonists
US12404336B2 (en) Bispecific antagonist comprising a LAG-3 binding domain
US12018073B2 (en) Antagonists targeting the TGF-β pathway
US20230340132A1 (en) ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES
US20250206828A1 (en) ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES AND THE USE THEREOF
JP2025511270A5 (https=)
US20250171542A1 (en) Anti-programmed death-ligand 1 (pd-l1) antibodies
WO2023192289A2 (en) Anti-trophoblast cell surface antigen 2 (trop-2) antibodies
HK40124840A (zh) 抗腺苷受体(a2ra)抗体及其用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 JUL 2023

SREP Specification republished